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http://dx.doi.org/10.1016/j.ccell.2014.09.009SUMMARYNeurofibromatosis type 1 is a tumor-predisposing genetic disorder. Plexiform neurofibromas are common
NF1 tumors carrying a risk of malignant transformation, which is typically fatal. Little is known about mech-
anisms mediating initiation and identity of specific cell type that gives rise to neurofibromas. Using cell-line-
age tracing, we identify a population of GAP43+ PLP+ precursors in embryonic nerve roots as the cells of
origin for these tumors and report a non-germline neurofibroma model for preclinical drug screening to iden-
tify effective therapies. The identity of the tumor cell of origin and facility for isolation and expansion provides
fertile ground for continued analysis to define factors critical for neurofibromagenesis. It also provides unique
approaches to develop therapies to prevent neurofibroma formation in NF1 patients.INTRODUCTION
The tumor predispositiondisorderNeurofibromatosis type I (NF1)
is among the most common human genetic diseases and is
caused by mutation in the NF1 tumor suppressor gene, which
encodes aGTPase Activating Protein (GAP) that negatively regu-
lates p21-RAS signaling (Ballester et al., 1990; Xu et al., 1990).
NF1patients havedefects in neural crest-derived tissues, leading
to a wide spectrum of clinical presentations, including develop-
mental, pigment or neoplastic aberrations of the skin, nervous
system, bones, endocrine organs, blood vessels, and the eyes
(Cichowski and Jacks, 2001; Ward and Gutmann, 2005; Zhu
et al., 2001). While NF1 patients are predisposed to developing
multiple tumor types (Cichowski et al., 1999; Jett and Friedman,
2010; Le and Parada, 2007; Shannon et al., 1994; Vogel et al.,
1999), the most common occurring are neurofibromas. Neurofi-
bromas are unique and complex tumors that contain proliferating
Schwann-like cells and other local supporting elements of the
nerve fibers, including perineurial cells, fibroblasts, and bloodSignificance
In this study, we utilized a genetically engineered mouse mod
broma. Using cell-lineage tracing, we showed that the embryon
nal nerve roots are the cells of origin for plexiform neurofibroma
immediate progenitors in the initiation of tumors, consistent w
primitive precursors and that most cells in an organ do not gene
ular cancer (the cells of origin) will permit greater understandin
for their treatment.
Canvessels, as well as infiltration of mast cells. Neurofibromas are
classified into different subtypes. However, for clinical and prog-
nostic implications, many clinicians simply refer to these tumors
as either dermal or plexiform. Dermal neurofibromas are exclu-
sively in the skin and occur in virtually all individuals with NF1.
They initially appear at puberty and increase in number with
age. Although similar to dermal neurofibromas at the cellular
andultrastructural levels, plexiformneurofibromasdevelop along
a nerve plexus or involve multiple nerve bundles and are capable
of forming large tumors. Unlike their dermal counterpart, plexi-
form neurofibromas are thought to be congenital and progres-
sively enlarge throughout life. They carry a risk of malignant
transformation that can metastasize widely and are often fatal.
Plexiform neurofibromas can occur anywhere along peripheral
nerve plexus. In fact, deep-tissue neurofibromas occur in 20%–
40% of adult NF1 patients (Tonsgard et al., 1998). The majority
of internal plexiformneurofibromasmanifest in thepara-spinal re-
gion associated with dorsal root ganglia (DRG). Their chance of
malignant transformation is much higher compared with otherel as a tool to identify the cell of origin for plexiform neurofi-
ic GAP43+ PLP+ Schwann cell precursors originate from spi-
s. Our studies point to the importance of stem cells and their
ith the notion that these neoplasms originate in a subset of
rate tumors. Identifying which cell type gives rise to a partic-
g of their pathogenesis and inform better design approaches
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Cells of Origin for Plexiform Neurofibromaformsof plexiformneurofibromas andcarries apoorer prognosis,
in part because they are not evident clinically in the early stage. In
addition, because of their location at the neural foramina of the
vertebral column, they can impinge on the spinal cord and nerve
roots, causing pain and neurological deficits. Thus, these para-
spinal neurofibromas represent a serious complication of NF1.
A large body of direct and indirect studies has provided
evidence that NF1 gene deletion is the requisite initial step that
precedes the cascade of interactions with other cell types in
the microenvironment as well as additional cell autonomous
modifications for neurofibromagenesis (Joseph et al., 2008; Le
et al., 2009; Wu et al., 2008; Zheng et al., 2008; Zhu et al.,
2002). Early speculation regarding the cells of origin for neurofi-
bromas came from genetic studies examining the participation
of different cell types including neural crest derivatives in the
pathogenesis of many of the clinical presentations of NF1,
including neurofibroma. In human neurofibromas, Schwann-
like cells with biallelic NF1 mutations are the most consistently
found cell type, leading to the argument that the tumors initiate
in Schwann cells or their earlier precursors. Indeed, genetic
mouse models have demonstrated that Nf1 deletion in the
Schwann cell lineage is the genetic bottleneck for neurofibroma
development (Cichowski et al., 1999; Joseph et al., 2008; Vogel
et al., 1999; Wu et al., 2008; Zheng et al., 2008; Zhu et al., 2002).
During the development of peripheral nerves, neural crest cells
generate Schwann cells in a process that parallels embryonic
development. Migrating neural crest stem cells emerge from
the dorsal horns of the neural tube and move through immature
connective tissue before the time of nerve formation and then
differentiate into Schwann cell precursors (SCPs). These SCPs
then become immature Schwann cells in the developing periph-
eral nerves until early neonatal stages. The differentiation of
immature Schwann cells to form the non-myelinating and myeli-
nating cells of mature nerves essentially occurs postnatally (Jes-
sen and Mirsky, 2005; Woodhoo and Sommer, 2008). Given that
the majority of plexiform neurofibromas in human are congenital
and generally detected at birth or in early infancy, theymust arise
from the early Schwann cell lineage. Indeed, genetic mouse
models have demonstrated that Nf1 deletion in the embryonic
Schwann cell lineage is the genetic bottleneck for neurofibroma
development (Cichowski et al., 1999; Joseph et al., 2008; Vogel
et al., 1999; Wu et al., 2008; Zheng et al., 2008; Zhu et al., 2002).
However, the exact developmental stage and embryonic loca-
tion of the Schwann cell lineage that initiate neurofibroma forma-
tion remain unknown. NF1 patients frequently have plexiform
neurofibromas in the para-spinal region at the neural foramina
associated with DRG. In addition, existing mouse models of
NF1 also develop neurofibromas at the DRG regions. We wish
to identify the cells of origin for these para-spinal plexiform
neurofibromas. We reason that they reside in the vicinity of the
embryonic DRGs or at the nearby nerve roots.
RESULTS
Loss of Nf1 in Embryonic DRG/Nerve Root Neurosphere
Cells Gives Rise to Classic Plexiform Neurofibroma
In Vivo
Recent studies have established the value of in vitro sphere
assay to identify cancer stem cells as well as neural stem/pro-696 Cancer Cell 26, 695–706, November 10, 2014 ª2014 Elsevier Incgenitor cells (Le et al., 2009; Williams et al., 2008). Therefore,
we examined whether Nf1-deficient embryonic DRG/nerve root
neurosphere cells (DNSCs) could contain the elusive cells of
origin of para-spinal neurofibromas. To obtain Nf1/ DNSCs,
we dissected DRGs/nerve roots from E13.5 Nf1flox/flox;
Rosa26(R26R) mouse embryos (Hall, 2006) and performed the
neurosphere culture. These neurosphere cells have high self-
renewal and proliferative potential (Figures S1A–S1D available
online). They were subsequently infected with adenovirus car-
rying the Cre recombinase (Ad-CMV-Cre) to ablate Nf1 and
generate Nf1/;LacZ+ DNSCs, which was verified by genomic
analysis of Nf1 (Figure 1A).
We next implanted Nf1/;LacZ+ DNSCs into the sciatic
nerves where close proximity to the nerve environment could
be achieved as previously established through an in vivo neuro-
fibromagenesis assay (Le et al., 2009). The transplanted
Nf1/;LacZ+ DNSCs gave rise to plexiform neurofibroma
within four months post implantation, whereas the transplanted
Nf1flox/flox;R26R controls showed no signs of tumor growth
(Figures 1Ba–1Bd and Table 1). These tumors exhibited all histo-
logical and immunohistochemical features of human plexiform
neurofibromas, including disorganized spindle cells, abundant
collagen matrix, heavy infiltration of mast cells and macro-
phages, expression of the Schwann cell marker S100b, and
GAP43 (Figure 1C; Figure S1E). To verify these tumors arise
from transplanted DRG/nerve root neurosphere cells rather
than from the host cells, we took advantage of the fact that
the transplant cells carried the LacZ marker gene but the host
did not. X-gal staining shown that these tumor cells were
LacZ+, which suggested that they arose from transplanted
Nf1/;LacZ+ DNSCs. Taken together, these data indicate that
when placed in a favorable microenvironment (in proximity to a
peripheral nerve), Nf1/;LacZ+ DNSCs can give rise to bona
fide plexiform neurofibromas. As such, these results show that
DNSCs have the full potential to generate neurofibromas and
indicate that the cells of origin for para-spinal neurofibromas
may be in the embryonic DRGs/nerve roots.
Cells of Origin for Para-Spinal Plexiform Neurofibromas
Are inside the Embryonic PLP+ Cells
Although we successfully induced neurofibroma formation by
transplanting embryonicNf1/DNSCs to sciatic nerves, it is un-
likely that all the embryonic DNSCs could give rise to plexiform
neurofibroma. In genetic mouse models, Nf1 ablation in embry-
onic Schwann cell lineage (PLP, Krox20, and DHH positive cells)
was sufficient to induce para-spinal plexiform neurofibromas (Le
et al., 2011; Wu et al., 2008; Zhu et al., 2002), suggesting that all
or at least part of the cells of origin might be inside these PLP+,
Krox20+, and DHH+ embryonic Schwann cell lineage. Therefore,
we next sought to determine this subpopulation within the em-
bryonic DNSCs that could give rise to neurofibroma.
To achieve this, we crossed Plp promoter-driven, tamoxifen-
inducible Cre (PlpCre-ERT) (Leone et al., 2003) transgenic mice
into a Nf1flox/flox;R26R-LacZ (Le et al., 2011) and Flox-stop-Flox
R26R-YFP (Chen et al., 2009) background to generate
PlpCre-ERT;Nf1flox/flox;R26R-LacZ-YFP mice. We selectively
ablated the embryonic Nf1 expression by administering 1 mg
tamoxifen orally at embryonic day 11.5 (E11.5) to pregnant
Nf1flox/flox;R26R-LacZ-YFP female mice that have been bred.
Figure 1. Loss of Nf1 in Embryonic DNSCs Gives Rise to Classic
Plexiform Neurofibroma In Vivo
(A) Diagram of experimental design: Isolation of DRGs/nerve roots from E13.5
Nf1flox/flox;R26R-LacZ embryos (a) and DNSCs culture (b); DNSCs were in-
fected with Ad-Cre to ablate Nf1; Ad-GFP was used as a control (c); and
Nf1/;LacZ+ and Nf1flox/flox ;LacZ DNSCs were implanted to right and left
sciatic nerves of nude mice, respectively (d).
(B) X-gal and H&E staining were performed on left (a and b) and right (c and d)
sciatic nerve.
(C) Tumor on right sciatic nerve was stained with antibody against S100b and
GAP43.
Blue scale bars, 500 mm. White and black scale bars, 50 mm. See also
Figure S1.
Table 1. The Cells of Origin for Spinal Plexiform Neurofibroma
Are inside the Embryonic PLP+ DNSCs
Genotype DNSCs
Selected
Ablation
of Nf1
Tumors/Nude
Mice Injected Percentage p Value
Nf1f/f;LacZ total Ad-Cre 5/6 83.3 0.015
total Ad-GFP 0/6 0
PlpCre-ERT;
Nf1f/f;LacZ-
YFP
YFP+ 13/20 65 <0.001
YFP 2/20 10
PlpCre-ERT;
Nf1f/f;LacZ-
YFP
YFP+ Ad-Cre 13/18 72.2 <0.001
YFP Ad-Cre 3/21 14.3
Krox20-Cre;
Nf1f/f;LacZ-
YFP
YFP+ 13/15 86.7 <0.001
YFP 3/15 20
Krox20-Cre;
Nf1f/f;LacZ-
YFP
YFP+ Ad-Cre 11/14 78.6 0.678
YFP Ad-Cre 9/14 64.3
Dhh-Cre;
Nf1f/f;LacZ-
YFP
Total Ad-Cre 11/16 68.8 1
YFP Ad-Cre 12/16 75
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Cells of Origin for Plexiform NeurofibromawithPlpCre-ERT;Nf1flox/flox;R26R-LacZ-YFPmalemice.We then
dissected the DRGs/nerve roots from embryos at E13.5 and per-
formed DNSCs culture. In order to isolate the PLP+ and PLP
from these E13.5 DNSCs, we used fluorescence-activated cell
sorting (FACS) to obtain the YFP+ and YFP DNSCs which rep-
resented PLP+ and PLPDNSCs, respectively. Next, these PLP+
and PLP DNSCs were transplanted in proximity to the sciaticCannerve of nude mice. Thirteen of 20 (65%) mice transplanted
with PLP+ DNSCs developed sciatic plexiform neurofibroma
(Table 1). By contrast, PLP DNSCs only led to neurofibroma
in 2 of 20 (10%)mice (Table 1), which suggests that PLP+ DNSCs
are more likely than PLP DNSCs to contain the cells of origin
and that neurofibroma development in the PLP DNSCs im-
planted mice is likely the result of contamination of PLP+ DNSCs
during the sorting process as loss of Nf1 is required for neurofi-
broma development. Therefore, given that theNf1 have been ab-
lated in PLP+ DNSCs and not in PLPDNSCs after the tamoxifen
induction, we could not exclude the possibility that Nf1 ablation
in PLPDNSCswould also give rise to neurofibroma. To address
this issue, both PLP+ and PLP DNSCs were infected with Ad-
CMV-Cre to generate the PLP+;Nf1/ and PLP;Nf1/DNSCs.
When transplanted to the sciatic nerve of nude mice, PLP+;
Nf1/ DNSCs maintained their higher capability to give rise to
neurofibroma (13 of 18, 72.2%), whereas PLP;Nf1/ DNSCs
could only give rise to plexiform neurofibroma in 3 out of 21
(14.3%) mice (Figure 2A and Table 1). Strikingly, we also
observed spontaneous transformation into malignant peripheral
nerve sheath tumors (MPNST) arising from a fraction of these
sciatic plexiform neurofibromas that originated from PLP+;
Nf1/ DNSCs (Figures 2Ai–2Al). This is consistent with human
clinical observations that about 10% of plexiform neurofibromas
undergo malignant transformation (Evans et al., 2002). These
data further indicate that the cells of origin might be within the
embryonic PLP+ DNSCs population.
However, since Nf1 ablation in Krox20+ and DHH+ embryonic
Schwann cell lineage could also give rise to para-spinal plexi-
form neurofibromas, we next examined whether the cells of
origin are also inside the embryonic Krox20+ or DHH+ DNSCs
(Wu et al., 2008; Zhu et al., 2002). We utilized the same strategies
as above using the Krox20-Cre and Dhh-Cre transgenic mice.
Unexpectedly, we found that not only the Krox20+;Nf1/ and
total DNSCs (contained DHH+;Nf1/ DNSCs) but also thecer Cell 26, 695–706, November 10, 2014 ª2014 Elsevier Inc. 697
Figure 2. The Cells of Origin for Para-Spinal
Plexiform Neurofibroma Are inside the Em-
bryonic PLP+ DNSCs
(A) FACS was performed to obtain the YFP+ and
YFP DNSCs from E13.5 PlpCre-ERT;Nf1flox/flox;
R26R-LacZ-YFP embryo, whose mother was
administered with tamoxifen at E11.5 (a and b).
Both YFP+ and YFP DNSCs were infected with
Ad-Cre to ablate Nf1, then injected to right and left
sciatic nerves of nude mice respectively (c). X-gal
and H&E staining were performed on the left and
right sciatic nerve (d–f). Sections of right sciatic
nerve were stained with antibody against S100b
(g) and GAP43 (h). A fraction of these sciatic
plexiform neurofibromas spontaneously trans-
formed into MPNST, exhibiting both benign and
malignant histologic characters (i–l). Immunofluo-
rescence staining of tumor on right sciatic nerve
shows expression of YFP as well as GAP43 and
S100b Schwann cell markers (m–r).
(B and C) A similar strategy to that in (A) was used
for YFP+ and YFP DNSCs derived from E13.5
embryos with genotype Krox20-Cre;Nf1flox/flox;
R26R-LacZ-YFP (B) and Dhh-Cre;Nf1flox/flox;
R26R-LacZ-YFP (C).
Blue scale bars, 500 mm. White and black scale
bars, 50 mm.
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Cells of Origin for Plexiform NeurofibromaKrox20;Nf1/ and DHH;Nf1/ DNSCs gave rise to neurofi-
broma with high percentage (Figures 2B and 2C and Table 1).
These results demonstrate that PLP+ DNSCs encompass the
cells of origin pool, whereas Krox20+;Nf1/ and DHH+;Nf1/698 Cancer Cell 26, 695–706, November 10, 2014 ª2014 Elsevier Inc.DNSCs might only account for partial
population of the cells of origin.
The PLP+ Cells of Origin Originate
in the Embryonic Nerve Roots
To determine if the embryonic Krox20+
and DHH+ cells are included within PLP+
cell population, we administered tamox-
ifen orally to mother mice at E11.5
to activate PlpCre-ERT to induce the
expression of YFP and genetically label
the PLP+ cells. We next performed immu-
nofluorescence staining against Krox20
and DHH and observed that the majority
of the endogenous Krox20 and DHH sig-
nals colocalized with YFP (PLP) in the
nerve root, DRG, and peripheral nerve
(Figure 3A), which indicated that most
of the Krox20+ and DHH+ cells were
included in the PLP+ cell population. We
also found that PlpCre+ (YFP+ cells) colo-
calized with endogenous PLP, suggest-
ing that the PlpCre+ population is inside
the endogenous PLP+ cell population
(Figure S2A).
We then took advantage of another
marker, LacZ, to compare the specific
expression pattern of LacZ among Plp,Krox20, and Dhh Cre mice. Specifically, for embryos with geno-
type PlpCre-ERT;R26R-LacZ, we gave the mother mice a single
dose of 4-hydroxytamoxifen, an active metabolic product of
tamoxifen that can be cleared relatively quickly from serum
Figure 3. Cells of Origin for Para-Spinal
PlexiformNeurofibromasAre inside the Em-
bryonic PLP+ Nerve Root Cells
(A) Representative frozen sections from E13.5
PlpCre-ERT;Nf1flox/flox;R26R-LacZ-YFP embryo,
whose mother was administered with tamoxifen at
E11.5, were stained for YFP, Krox20, DHH, and
DAPI. NR, nerve root; DRG, dorsal root ganglia.
(B–D) X-gal and H&E staining were performed on
embryos with genotype PlpCre-ERT;R26R-LacZ
(B, mother mouse was administered with 4-hy-
droxytamoxifen at E9.5), Krox20-Cre;R26R-LacZ
(C), and Dhh-Cre;R26R-LacZ (D) from E10.5 to
E13.5. Arrow, area of enlarged view; arrow head,
nerve roots; star mark, DRG.
(E) DRG and dorsal nerve root were separated
from E13.5 embryos and cultured in neurosphere
culture conditions.
(F) Nerve root derived neurospheres immuno-
stained for Nestin, GFAP, S100b, P75, Ki67, and
DAPI.
(G) Immunostaining of nerve root derived neuro-
sphere cells cultured in neurosphere medium (a, c,
e, and g) or differentiation medium (b, d, f, and h)
with antibodies against S100b, GAP43, bIII-
tubulin, and Olig2.
Blue scale bars, 500 mm. White and black scale
bars, 50 mm. See also Figure S2.
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Cells of Origin for Plexiform Neurofibroma(Robinson et al., 1991), to acutely induce the expression of LacZ
in PLP+ cells at E9.5. On the other hand, Krox20-Cre and Dhh-
Cre are noninducible and, therefore, tamoxifen induction is not
needed. We isolated the embryos at different time points and
performed whole-mount X-gal staining. For the PlpCre-
ERT;R26R-LacZ mice, the LacZ (PLP) positive staining beganCancer Cell 26, 695–706, Nto show up inside the nerve roots,
DRGs, and trigeminal ganglion (TG) at
E10.5 (Figure 3B). Histological analysis
indicated that the LacZ+ (PLP+) cells
were mainly inside the nerve roots and
only few scattered LacZ+ (PLP+) cells
could be seen in DRG (Figure 3B). From
E11.5 to E13.5, more LacZ+ (PLP+) cells
appear in nerve roots, DRGs, TGs, and
eventually peripheral nerves (Figure 3B).
In contrast, in the Krox20-Cre mice, the
LacZ+ (Krox20+) cells first appear in nerve
roots at E11.5 and stay in nerve roots until
E13.5 when some peripheral nerves
started to express the LacZ (Krox20).
However, there were very few LacZ+
(Krox20+) cells inside theDRG (Figure 3C).
Similarly, in Dhh-Cremice, we could only
observe very few LacZ+ (DHH+) cells in
nerve roots after E11.5. From E12.5 to
E13.5, more LacZ+ (DHH+) cells were
detected only at nerve roots and some
of the peripheral nerves (Figure 3D),
which were consistent with previous find-
ings that Dhh transcripts were expressedby SCPs both in the dorsal and ventral roots at E13 (Parmantier
et al., 1999). All of these data suggest that the PLP+ cells first
appear in embryonic nerve roots at least one day earlier and in
a wider cell population than that of Krox20+ and DHH+ cells
and that PLP+ DNSCs represent a wider pool for the cells of
origin. Consistently, when we carefully separated out the E13.5ovember 10, 2014 ª2014 Elsevier Inc. 699
Figure 4. Phenotypic Analysis Identifies the
PLP+ Cells of Origin as Embryonic Schwann
Cell Precursors
(A) DNSCs obtained from E13.5 PlpCre-ERT;
Nf1flox/flox;R26R-YFP embryos, whosemother was
administered with tamoxifen at E11.5, were
stained for YFP, DAPI, and lineagemarkers: Nestin
(a), P75 (b), BLBP (c), GFAP(d), S100b (e), bIII-
tubulin (f), and GAP43 (g–i).
(B) Formalin fixed paraffin embedded sections
from E13.5 PlpCre-ERT;Nf1flox/flox;R26R-YFP em-
bryos, whose mother was administered with
tamoxifen at E11.5, were stained for YFP, DAPI,
and lineage markers: GAP43 (a–c), Nestin (d), P75
(e), BLBP (f), bIII-tubulin (g), GFAP (h), and S100b
(i). DRG, dorsal root ganglia; NR, nerve root; PN,
peripheral nerve; SC, spinal cord.
All scale bars, 50 mm. See also Figure S3.
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Cells of Origin for Plexiform Neurofibromaembryonic dorsal nerve roots from the DRGs, we found that only
the embryonic dorsal nerve roots could robustly give rise to neu-
rospheres, but not the E13.5 DRGs (Figure 3E). However, in adult
mice, we found that the DRGs can also give rise to neurospheres
(Figure S2B). Further immunofluorescence analyses demon-
strate that these embryonic nerve roots generated neurosphere
cells that express neural crest markers (Nestin and P75), imma-
ture Schwann cell marker GFAP, and proliferation marker Ki-67,
but not the mature Schwann cell marker S100b (Figure 3F).700 Cancer Cell 26, 695–706, November 10, 2014 ª2014 Elsevier Inc.Under differentiation conditions, these
neurosphere cells could differentiate
into Schwann cells and neurons, but not
the oligodendrocytes (Figure 3G). These
data further narrow the candidate cells
of origin to PLP+ cells in the embryonic
nerve roots.
Phenotypic Analysis Identifies the
PLP+ Cells of Origin as Embryonic
Schwann Cell Precursors
Boundary cap (BC) cells are transient
neural crest-derived population of stem
cells located at the dorsal root entry
zone and give rise to most Schwann cells
in the dorsal roots and DRGs (Coulpier
et al., 2009; Hjerling-Leffler et al., 2005;
Topilko et al., 1994). Therefore, BC cells
might be the embryonic neurofibroma tu-
mor cells of origin. However since Krox20
is a marker of BC cells and both Krox20+;
Nf1/ andKrox20;Nf1/DNSCs could
give rise to sciatic plexiform neurofi-
broma, this indicates that BC cells are un-
likely to be the cells of origin, but rather an
even earlier cell that is PLP+. To pheno-
typically characterize these PLP+ cells
of origin, we gavaged mother mice with
tamoxifen at E11.5, harvested DRGs/
nerve roots from PlpCre-ERT;Nf1flox/flox;
R26R-YFP embryos at E13.5 for neuro-sphere cell culture, and performed immunofluorescence ana-
lyses. We found that the majority of neurosphere cells, either
YFP+(PLP+) or YFP(PLP), expressed Nestin and P75, which
confirms that they originate from the neural crest (Figures 4Aa
and 4Ab). We also observed the expression of embryonic
Schwann cell markers BLBP and GFAP in the minority of both
YFP+(PLP+) and YFP(PLP) cells, but none expressed the
immature and mature Schwann cell marker S100b (Figures
4Ac–A4e). In addition, the majority of YFP+(PLP+) cells did not
Figure 5. Cell Lineage Tracing Reveals
PLP+ Precursors in the Embryonic Nerve
Roots as the Cells of Origin for Plexiform
Neurofibromas
(A) X-gal staining of whole spinal cord, DRGs
and partial peripheral nerves from PlpCre-ERT;
Nf1flox/;R26R-LacZ mouse, whose mother was
administered with tamoxifen at E9.5. There is
strong X-gal staining in the enlarged DRGs (star
mark), enlarged intercostal nerve (arrow head),
and nerve root (arrow).
(B) H&E and immunohistochemical staining for
GAP43 and S100b in sections from these enlarged
LacZ+ DRGs (star mark in A).
(C) H&E staining of the DRG and its associated
enlarged intercostal nerve (EIN) in (A) (arrow head).
Enlarged intercostal nerve was also stained for
GAP43 and S100b.
(D) Representative H&E and immunohistochem-
ical analyses of early neurofibroma in dorsal root
and associated normal DRG (arrow in A). DRG,
dorsal root ganglia; DR, dorsal root; SC, spinal
cord; VR, ventral root.
Blue scale bars, 500 mm. All other scale bars,
50 mm.
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Cells of Origin for Plexiform Neurofibromaexpress neuronal marker bIII-tubulin (Figure 4Af). Strikingly,
every YFP+(PLP+) cell also expressed GAP43, a Schwann cell
marker that is known to first appear at the precursor stage (Fig-
ures 4Ag–4Ai), and Sox10, a marker for neural crest origin and
future Schwann cell lineage (Figure S3A) (Kalcheim and Rohrer,
2014). Because these PLP+GAP43+ cells are also P75 positive
but S100b negative, they are at Schwann cell precursor stage
(Jessen and Mirsky, 2005). It is well known that cell culture
in vitro may vary from that in vivo. Therefore, we also character-
ized these PLP+ cells in E13.5 PlpCre-ERT;Nf1flox/flox;R26R-YFP
embryos and observed that YFP+(PLP+) cells were colocalized
with GAP43 mainly at nerve roots (Figures 4Ba–4Bc). Similar to
our in vitro data, they also expressed Nestin, P75, BLBP, and
Sox10 (Figures 4Bd–4Bf; Figure S3B). They were also colocal-
ized with bIII-tubulin (Figure 4Bg). However, they did not express
GFAP and S100b in vivo (Figures 4Bh and 4Bi). These findings
indicate that PLP+GAP43+ cells in the embryonic nerve roots
are SCPs and that they may be the elusive cells of origin for
para-spinal plexiform neurofibroma.
Cell Lineage Tracing Confirms the PLP+ Precursors
Originate in the Embryonic Nerve Roots as the Cells of
Origin for Plexiform Neurofibromas
Tumor cells of origin are difficult to identify by characterizing
cells within terminal stage tumors. A more definitive approach
is to genetically label specific lineage early in development forCancer Cell 26, 695–706, Nfate tracing prior to tumorigenesis. X-gal
staining demonstrates that LacZ+(PLP+)
cells are mainly located in nerve roots
at E10.5 when we gave 4-hydroxyta-
moxifen to pregnant mother mice at
E9.5 (Figure 3B). If these Nf1 ablated
LacZ+(PLP+) nerve root cells would
give rise to neurofibroma, then neurofi-broma cells should carry the marker gene LacZ. Therefore,
we crossed PlpCre-ERT;Nf1flox/flox;R26R-LacZ male mice
with Nf1flox/;R26R-LacZ female mice. We then administered
4-hydroxytamoxifen to pregnant mother mice for one dose at
E9.5. At 7 months of age, PlpCre-ERT;Nf1flox/;R26R-LacZ
progenies from these crosses began to show classic signs
of illness: lethargy, weight loss, and paralyzed hind limbs.
We observed the presence of plexiform neurofibromas with
strong positive X-gal staining in close proximity to the cervical
and thoracic DRGs (Figure 5A). Because PlpCre-ERT mediates
labeling solely at the time of tamoxifen administration at E9.5,
X-gal positive staining of neurofibroma cells demonstrates
unambiguously that the labeled neurofibromas were derived
from E9.5 PLP+ precursors in the embryonic nerve roots.
Histopathological analysis of these tumors indicated that
the tumors exhibited cardinal features of plexiform neurofi-
bromas (Figure 5B). Strikingly, we also observed plexiform
neurofibroma developed along the intercostal nerve whose
associated DRG appears histologically normal (Figure 5C). In
addition, we identified the earliest form of neurofibroma exhib-
iting LacZ positive staining: classic pathological characteristics
of neurofibroma and expressing Schwann cell marker S100b
and GAP43 at the dorsal nerve roots near the DRG (Figure 5D).
Together, these findings point to the PLP+;GAP43+ SCPs in
the embryonic nerve roots as the cells of origin for plexiform
neurofibroma.ovember 10, 2014 ª2014 Elsevier Inc. 701
Figure 6. Therapeutic Effect of MAPK Signaling Inhibitor on DNSC-Derived Plexiform Neurofibroma
(A) Diagram of experimental design for testing therapeutic effect of PD0325901 on plexiform neurofibroma.
(B) Immunostaining of ERK1/2 (total) and p-ERK1/2 (phosphorylated ERK) in E13.5 Nf1/ DNSCs derived sciatic plexiform neurofibroma (a). Fold change of
luminescence countmeasured during PD0325901 or vehicle treatment (b). After 4weeks of treatment, both PD0325901 and vehicle treatment groupwere divided
into two subgroups: discontinued PD0325901 or continued PD0325901 and discontinued vehicle treatment or continued vehicle treatment subgroups for an
additional 4 weeks. Tumors were then harvested for X-gal staining (c) and immunostaining for ERK1/2 and p-ERK1/2 (d). Statistics were represented as the
mean ± SEM (*p < 0.05).
Blue scale bars, 500 mm. All other scale bars, 50 mm. See also Figure S4.
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Drug Screening
The Nf1 gene encodes for neurofibromin, a Ras GTPase acti-
vating protein (GAP), and thus negatively regulates the RAS
signaling pathway (Rubin and Gutmann, 2005). This has promp-
ted the use of specific MAP Kinase pathway inhibitors to coun-
teract Nf1 loss-mediated tumor development (Chang et al.,
2013; Jessen et al., 2013; Staser et al., 2013) or to treat Nf1
mutant animals in the effort to restore abnormal brain develop-
ment and cognitive function (Li et al., 2012; Lush et al., 2008;
Wang et al., 2012). To determine if our non-germline plexiform
neurofibroma model could be used as a rapid preclinical thera-
peutic drug screening tool to identify effective therapies, we
used a highly selective pharmacological inhibitor of MEK,
PD0325901, which blocks activation and phosphorylation of
ERK1/2 (Chang et al., 2013), to test whether inhibition of the
Ras/Raf/MEK/ERK signaling pathway can prevent neurofibroma
progression in our plexiform neurofibroma model.
In order to monitor the proliferation of tumor cells, we labeled
these neurofibroma cells with Luciferase by crossing the
Nf1flox/flox;R26R-LacZ (Le et al., 2011) mice with Flox-stop-Flox702 Cancer Cell 26, 695–706, November 10, 2014 ª2014 Elsevier IncR26R-Luciferase mice to generate Nf1flox/flox;R26R-LacZ-
Luciferase mice. We then harvested E13.5 DNSCs and infected
with Ad-CMV-Cre to generate Nf1/;R26R-LacZ-Luciferase
DNSCs. We transplanted these Nf1/;R26R-LacZ-Luciferase
DNSCs to sciatic nerves of nudemice to generate plexiform neu-
rofibromas. Mice were randomly assigned to PD0325901 treat-
ment (5 mg/kg/day, 5 day/week) or vehicle as a control group
(Figure 6A). We also tested if the MAPK pathway is activated in
our neurofibromas and found that the ERK pathway is highly acti-
vated in the tumor tissues as shown by immunohistochemistry
analysis (Figure 6Ba). We then started the treatment right after
the transplantation. A striking reduction in luciferase signal was
observed even after only one week of PD0325901 treatment
(p < 0.01). Continued treatment of PD0325901 further inhibited
the proliferation of tumor cells. After 4 weeks of PD0325901
treatment, tumor cell proliferation was almost completely blunt-
ed as demonstrated by the diminishing luciferase signal. On the
other hand, the luciferase signal in vehicle treatment group
increased more than 10 times after 4 weeks of treatment
(Figure 6Bb). These data suggested that the PD0325901 could
effectively inhibit the proliferation of plexiform neurofibroma..
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PD0325901 would be sustained after stopping the PD0325901
treatment. To answer this question, we divided the
PD0325901 treatment group into two subgroups: discontinued
PD0325901 treatment after 4 weeks or continued PD0325901
treatment for an additional 4 weeks in another group of mice.
Similar to this, we also divided the vehicle treatment group into
two subgroups based on continuing or discontinuing vehicle
treatment for another 4 weeks. We again used the luciferase
signal as a surrogate marker for tumor growth. We observed
that continued treatment of PD0325901 further blunted the pro-
liferation of neurofibroma; however, they regained the prolifera-
tive capacity after PD0325901 withdrawal. Eight weeks after
transplantation of DNSCs, we sacrificed all mice and performed
X-gal staining of the sciatic nerves. Vehicle treatment groups
(8 weeks or 4 weeks) developed very large LacZ+ neurofibromas,
4-week PD0325901 treatment dramatically reduced the growth
of neurofibromas, while 8-week PD0325901 treatment almost
completely prevented the proliferation of neurofibroma (Fig-
ure 6Bc; Figure S4). Consistently, ERK1/2 phosphorylation was
also reduced in both PD0325901 treatment groups compared
with vehicle treatment groups (Figure 6Bd). All of these data
showed the requirement of sustained Ras/Raf/MEK/ERK
signaling for neurofibroma growth and that continuous
PD0325901 treatment is effective in restraining this growth.
Thus, our non-germline plexiform neurofibroma model provides
a powerful approach for preclinical therapeutic drug screening to
identify effective therapies for human clinical trials to prevent
neurofibroma formation in NF1 patients, where none exist today.
DISCUSSION
Recent progress in cancer research points to the importance of
stem cells and their immediate progenitors in the initiation and
maintenance of many tumors, consistent with the notion that
these neoplasms originate in a subset of primitive precursor cells
and that most cells in an organ do not generate tumors (Alcan-
tara Llaguno et al., 2009; Barker et al., 2009; Bonnet and Dick,
1997; Chen et al., 2012a; Goldstein et al., 2010; Le et al., 2009;
Reya et al., 2001; Tysnes, 2010). Identifying which cell type gives
rise to a particular cancer (the cells of origin) will permit greater
understanding of their pathogenesis and inform better design
approaches for their treating. In this study, we utilized a geneti-
cally engineered mouse model as a tool to identify the cells of
origin for plexiform neurofibroma. Using cell lineage tracing, we
demonstrated that the embryonic PLP+;Nf1/ SCPs, which
originate from spinal nerve roots, give rise to plexiform neurofi-
broma not only in para-spinal areas but also in distal peripheral
nerve. We also report a non-germline model for plexiform neuro-
fibroma that can be used broadly as preclinical models for ther-
apeutic testing.
A large body of direct and indirect studies has provided evi-
dence that Nf1 gene deletion is the requisite initial step that pre-
cedes neurofibromagenesis (Joseph et al., 2008; Le et al., 2009;
Wu et al., 2008; Zheng et al., 2008; Zhu et al., 2002). Cichowski
et al. (1999) addressed this issue elegantly when they generated
chimeric mice by injecting LacZ+ Nf1/ ES cells into wild-type
blastocysts. These mice developed microscopic neurofibromas
derived from the injectedEScells, demonstrating the requirementCanofNf1 homozygosity for tumor formation (Cichowski et al., 1999).
However, the extent of chimerism in thesemice occurs randomly
and cannot be controlled genetically. As a result, it is difficult to
establish the cells of origin for these tumors. Conditional deletion
ofNf1 fromembryonicneural crest stemcells (NCSCs) usingWnt-
1-Cre transgenic mice leads to a transient increase in NCSC
frequency and self-renewal, but the isolated NCSCs fail to form
tumors upon transplantation (Joseph et al., 2008), suggesting
that early NCSC derivatives may not contain potential cells of
origin for plexiform neurofibroma. This observation indicates
that later NCSC derivatives give rise to plexiform neurofibromas.
Consistently, ablation of Nf1 in Schwann cells using P0A-Cre;
Nf1flox/ or Dhh-Cre;Nf1flox/flox mice, which deletes Nf1 continu-
ously from early SCPs through mature cells, efficiently induce
neurofibromas development (Wu et al., 2008; Zheng et al.,
2008). However, the Cre recombinase transgenes used in these
two studies compromise Nf1 function at the early Schwann cell
stagesof development (at E12.5), and theCre recombinase activ-
ity persists through thematureSchwanncell stage. Therefore, it is
not possible to identify or exclude any particular Schwann cell
developmental stage as the critical one forNf1 loss-mediated tu-
mor development. The interpretation of the data instead rests on
correlations relating to detectable appearance of abnormal cells
or structures. An alternative approach that can in theory provide
a more precise evaluation of the evolution of NF1-associated
tumors is the application of inducible Cre/loxP technology that al-
lows temporal and spatial ablation of NF1 function in Schwann
cells. Twodifferent studies show thatacute lossofNf1 in bothem-
bryo and adult can lead to plexiform neurofibroma formation (Le
et al., 2011; Mayes et al., 2011). The fact that Nf1 inactivation in
adult mice also gives rise to neurofibroma, albeit at a much lower
frequency (Le et al., 2011), indicates that either (1) mature
Schwann cells can, in rare cases, give rise to neurofibroma or
(2) that rare populations of progenitor cells persist within the adult
peripheral nervous system.
The notion that mature Schwann cells have the capability to
give rise to plexiform neurofibromas is less evident. NF1 patients
rarely present with plexiform tumors for the first time as adults
(Ferner, 2007). As aforementioned, Schwann cell development
and terminal differentiation into myelinating cells mostly occurs
postnatally. If mature Schwann cells as a whole can give rise
to neurofibromas when loss of heterozygosity (LOH) occurs in
adulthood, then it would be anticipated that plexiform tumors
should develop widely in PlpCre-ERT mice induced postnatally
since Cre-mediated recombination remains efficient in mature
Schwann cells. It is not likely that the Schwann cell lineage un-
dergoes immature to mature transition en masse at tightly
defined times from the NCSC stage, to the precursor stage, to
the immature stage, and onward to more differentiated stages.
Instead, gradients of cells transition and migrate over extended
periods with considerable overlap between the disappearance
of one population and the emergence of another. Therefore, re-
maining compartments of precursor Schwann cells may also
persist into adulthood and retain the capacity to form plexiform
neurofibromas within the peripheral nerves. Indeed, given
that embryonic nerve roots associate tightly with DRGs and
that the harvested DRGs almost always contaminate with
nerve roots, we carefully separated out the early embryonic
dorsal nerve roots from the DRGs for neurosphere culture.cer Cell 26, 695–706, November 10, 2014 ª2014 Elsevier Inc. 703
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roots could robustly give rise to neurosphere but not the E13.5
DRGs. However, in adult mice, we found that the DRGs can
give rise to neurospheres and neurofibroma when Nf1 was abla-
ted and implanted into the sciatic nerves (data not shown).
Consistently, when we acutely labeled the PLP+ precursor cells
with LacZ only in nerve roots at E10.5, we also observed plexi-
form neurofibroma developed in the peripheral nerve distal to
the DRG. All of the data suggest that at least some of the cells
of originmight migrate out along the nerve roots-DRG-peripheral
nerve and retain the capacity to form neurofibroma later in life.
In the conditional knockout model using Cre/loxP technology,
theKrox20-Cre;Nf1flox/floxmice (containingNf1/Schwann cells
andNf1+/+microenvironment) do not develop neurofibromas. On
the other hand, the Krox20-Cre;Nf1flox/mice (containing Nf1/
Schwann cells and Nf1+/microenvironment) develop plexiform
neurofibromas (Zhu et al., 2002), demonstrating the essential
role for the heterozygous environment in the development of
neurofibroma. In another mouse model, a more robust Dhh-Cre
driver causes plexiform neurofibroma formation in an Nf1-wild-
type background (Wu et al., 2008). In the current study, the PLP+;
Nf1/DNSCs could also effectively give rise to plexiform neuro-
fibromas when transplanted into the sciatic nerves of nude mice,
which also have an Nf1-wild-type background. It is important to
emphasize here that under these conditions, a large group of
SCPs undergoes Nf1 LOH simultaneously and can therefore vie
with the wild-type environment more efficiently than when only
one or a very few isolated SCPs undergo LOH. In NF1 patients
that harbor germline heterozygous NF1 mutations, given the
defined time of gestation and size of neural crest compartment,
inactivation of the other normal NF1 in the Schwann cell lineage
must be rare and stochastic, such that single cells undergo
completely inactivation ofNF1 in a largepool of otherwise hetero-
zygous NF1mutant cells. In this setting, the increased secretion
of SCF or other factors from heterozygous cells, including mast
cells, in the tumor microenvironment provides a permissive con-
dition to foster tumor growth (Yang et al., 2008). Therefore, in the
experimental setting, one possible advantage of having a large
pool of precursors undergoing LOH would be a rapid and dra-
matic increase in cytokine and growth factor secretion that could
be sufficient to elicit wild-type mast cells without the need for the
hypersensitive heterozygous state of the latter. As such, in the
physiologic scenario, one would envision a rare Schwann cell
undergoing LOH that would normally disappear except for the
response of theNf1-heterozygousmicroenvironment that assists
it to form a tumor. In another scenario, contribution of amultitude
of cells that have undergone LOH may override the otherwise
requisite contributions from other factors, such as heterozygous
mast cells or other cells in the microenvironment, to induce
neurofibroma development.
Although the tumor microenvironment is critical for neurofi-
broma formation (Le et al., 2009; Yang et al., 2008), intrinsic pro-
liferative signals such as those in theMAPKpathways are equally
essential. Therefore, both the tumor microenvironment and
MAPK pathways have been targeted in the preclinical setting
to define clinically relevant pharmacodynamic variables and
evaluating duration of drug effects on individual tumor (Jessen
et al., 2013; Yang et al., 2008). The purpose of preclinical drug
screening is to select the most effective and safe compound704 Cancer Cell 26, 695–706, November 10, 2014 ª2014 Elsevier Incfrom a large library. Our non-germline model for plexiform neuro-
fibroma enables high efficiency of tumorigenesis and has amuch
shorter latency. Therefore, it is a reliable and robust model for
in vivo drug screening with a quantifiable and reproducible
outcome measure (via bioluminescent scan) to select lead com-
pounds for clinical assessment. In addition, the ability to isolate
embryonic PLP+ GAP43+ cells for ex vivo expansion and Nf1
ablation to generate classic sciatic plexiform neurofibromas al-
lows flexible and speedymanipulation withmultiple genetic tools
to delineate additional pathways that are perturbed upon the
loss of Nf1, which are essential for neurofibroma development.
In conclusion, the identity of the tumor cells of origin and the
facility for isolation and expansion for genetic alterations provide
fertile ground for continued analysis to identify additional intrinsic
and extrinsic factors within the tumor microenvironment that
likely play essential roles in neurofibroma genesis. It is reason-
able to speculate that lessons learned from investigating themo-
lecular interactions between the neurofibroma cells of origin and
their microenvironment will provide us approaches to develop
effective therapies to delay and possibly prevent neurofibroma
formation in NF1 patients.
EXPERIMENTAL PROCEDURES
Mice
Animal care and use were approved by the Institutional Animal Care and
Use Committee at University of Texas Southwestern Medical Center. The
Nf1flox/ and Nf1flox/flox mice have been described previously (Zhu et al.,
2002). For conditional ablation of Nf1, we used a tamoxifen-inducible Cre
line, the PlpCre-ERT2 transgenic mice (Leone et al., 2003), and two non-induc-
ible Cre lines, Krox20-Cre and Dhh-Cre (Limpert et al., 2013; Zhu et al., 2002).
The Rosa26-YFP reporter mice were described previously (Chen et al., 2009).
The ROSA26-lacZ and ROSA26-Luciferase reporter mice were obtained
from the Jackson Laboratories.
Tamoxifen and 4-Hydroxytamoxifen Induction
Tamoxifen (Sigma-Aldrich) and 4-hydroxytamoxifen was dissolved in a
sunflower oil/ethanol mixture (9:1) at 10 mg/ml and 1 mg/ml, respectively.
For embryonic induction, the pregnant mice were gavaged orally with 1 mg
of tamoxifen or 0.2 mg of 4-hydroxytamoxifen at E11.5 or E9.5, respectively.
Cell Culture and Differentiation Assays
Mouse embryos were removed from anesthetized 13.5-day-old pregnant
female mice. Embryos were sacrificed. The spinal cord of each embryo was
removed, and DRGs/nerve roots were dissected from the vertebral column
with the aid of stereomicroscope. Fine scissors was used to cut and separate
the nerve roots and DRGs. DRG and/or nerve root neurosphere culture was
performed as previously described (Le et al., 2009; Patel et al., 2014; Ratner
et al., 2006). For cell proliferation assay, the single sphere cells were seeded
to a 6-well plate coated with poly-D-lysine/laminin (4.0 3 103 cells per well)
for monolayer culture. The cell numbers of 3 wells were counted every 24 hr
for 5 days. For differentiation assays, we seeded 5.0 3 103 cells per well of
an 8-chamber slide coated with poly-D-lysine/laminin and cultured with fresh
media containing B27 + 5% fetal bovine serum for 7–14 days. Then we fixed
the cells with 4%paraformaldehyde for 30min and performed immunostaining
for lineage markers.
Fluorescence-Activated Cell Sorting
We harvested YFP+ and YFP DNSCs using FACSAria instrument (BD Biosci-
ences) equipped with a 488 nm solid-state laser.
Histology, Immunostaining, and X-Gal Staining
For hematoxylin and eosin (H&E) histology analysis, tissue specimens were
harvested and fixed with 10% formalin in PBS for 1 day and subsequently.
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ufacturer’s protocol (StatLab). The dilutions of primary antibodies used in
immunohistochemistry and immunofluorescence studies were as follows: b
III-tubulin (rabbit, 1:2000, Sigma-Aldrich), BLBP (rabbit,1:800, Millipore),
CD31 (rabbit, 1:200, Abcam), BrdU (rat, 1:400, Abcam), Cleaved Caspase-3
(rabbit, 1:100, Cell Signaling Technology), DHH (rabbit,1:200, Santa Cruz
Biotechnology), total ERK1/2 (rabbit,1:250, Cell Signaling Technology), phos-
pho-ERK1/2 (rabbit,1:400, Cell Signaling Technology), GAP43 (rabbit, 1:1000,
Abcam), GFAP (rabbit, 1:2000, DAKO), GFP (goat, 1:300, Rockland), Krox20
(rabbit, 1:200, Covance Research Products), Nestin (rabbit, 1:5000, Abcam),
P75 (rabbit, 1:400, Millipore), PLP (rabbit, 1:800, Abcam), S100 b (rabbit,
1:5000, DAKO), Sox10 (Goat,1:400, Santa Cruz Biotechnology), and Vimentin
(mouse, 1:800, Santa Cruz Biotechnology).
For X-gal staining, after total body perfusion with 4% paraformaldehyde,
tissues or embryos were harvested, equilibrated in 30% sucrose in PBS
overnight at 4C, and stained with X-gal at 30C overnight. The tissues were
then postfixedwith 10% formalin, paraffin embedded, sectioned, and counter-
stained with hematoxylin.
Transplantation Experiments
Sciatic nerve implantation of DNSCs was performed as previously reported
(Chen et al., 2012b). Briefly, mice were anesthetized by intraperitoneal injec-
tion of 120 ml of a mixture of ketamine (10 mg/ml) and xylazine (1 mg/ml) solu-
tion. A skin incision was made above the femur. Using iris scissors, a pocket
was created within the quadriceps muscles to expose the sciatic nerve. The
40 ml of L15 medium containing 1 3 106 viable DNSCs was then deposited
into this pocket so that DNSCs can be in contact with the SN. The quadriceps
muscles were then closed with 4-0 Vicryl suture, and the skin was closed
with 5-0 prolene suture. Mice were allowed to recover from anesthesia, then
subject to MEK Inhibitor treatment and bioluminescent imaging.
MEK Inhibitor Treatment
MEK inhibitor PD0325901 were kindly provided by Dr. Kevin Shannon.
PD0325901 was dissolved in vehicle (0.5% hydroxypropyl methylcellulose
with 0.2% Tween 80; Sigma-Aldrich) at a concentration of 1 mg/ml. The
solution was administered orally at the dosage of 5 mg/kg (body weight) per
mouse, once per day, for 5 days/week.
Bioluminescent Imaging
Bioluminescent imaging was performed as described previously (Chau et al.,
2014). Briefly, mice were injected with 160 ul 20 mg/ml D-Luciferin Potassium
Salt (Perkin Elmer) in 0.9% sterile NaCl, and total flux was quantified using IVIS
Lumina II (Caliper Life Sciences) weekly.
Statistics
All data are displayed as the mean ± SEM unless specified otherwise. A
two-tailed t test and Fisher exact test were applied as appropriate to evaluate
statistical significance (p < 0.05 was deemed statistically significant).
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures
and four figures and can be found with this article online at http://dx.doi.org/
10.1016/j.ccell.2014.09.009.
AUTHOR CONTRIBUTIONS
L.Q.L. contributed to conception and experimental designs, data collection
and/or assembly, data analysis and interpretation, manuscript writing, and
final approval of manuscript. Z.C. contributed to experimental designs, data
collection and/or assembly, data analysis and interpretation, and manuscript
writing. C.L., A.J.P., C.-P.L., and Y.W. contributed to data collection.
ACKNOWLEDGMENTS
We thank all members of the L.Q.L. lab and Dr. Luis Parada, Dr. Kristjan
Jessen, Dr. Rhona Mirsky, and Dr. Wei Mo for helpful suggestions and discus-
sions. We also thank Dr. Ueli Suter for the PlpCre-ERTmice. A.J.P. and C.-P.L.Canare recipients of the Young Investigator Awards from Children’s Tumor Foun-
dation. L.Q.L. holds a Career Award for Medical Scientists from the Burroughs
Wellcome Fund. This work was supported by funding from the Elisabeth Reed
Wagner Fund for Research and Clinical Care in Neurofibromatosis and Cardio-
thoracic Surgery, the Disease-Oriented Clinical Scholar Program, the National
Cancer Institute of the NIH grant number R01 CA166593, and U.S. Department
of Defense grant number W81XWH-12-1-0161 to L.Q.L.
Received: May 14, 2014
Revised: July 18, 2014
Accepted: September 19, 2014
Published: October 30, 2014
REFERENCES
Alcantara Llaguno, S., Chen, J., Kwon, C.H., Jackson, E.L., Li, Y., Burns, D.K.,
Alvarez-Buylla, A., and Parada, L.F. (2009). Malignant astrocytomas originate
from neural stem/progenitor cells in a somatic tumor suppressor mouse
model. Cancer Cell 15, 45–56.
Ballester, R., Marchuk, D., Boguski, M., Saulino, A., Letcher, R., Wigler, M.,
and Collins, F. (1990). The NF1 locus encodes a protein functionally related
to mammalian GAP and yeast IRA proteins. Cell 63, 851–859.
Barker,N.,Ridgway,R.A., vanEs, J.H., vandeWetering,M.,Begthel,H., vanden
Born, M., Danenberg, E., Clarke, A.R., Sansom, O.J., and Clevers, H. (2009).
Crypt stem cells as the cells-of-origin of intestinal cancer. Nature 457, 608–611.
Bonnet, D., and Dick, J.E. (1997). Human acute myeloid leukemia is organized
as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3,
730–737.
Chang, T., Krisman, K., Theobald, E.H., Xu, J., Akutagawa, J., Lauchle, J.O.,
Kogan, S., Braun, B.S., and Shannon, K. (2013). Sustained MEK inhibition
abrogates myeloproliferative disease in Nf1 mutant mice. J. Clin. Invest. 123,
335–339.
Chau, V., Lim, S.K., Mo, W., Liu, C., Patel, A.J., McKay, R.M., Wei, S., Posner,
B.A., De Brabander, J.K., Williams, N.S., et al. (2014). Preclinical therapeutic
efficacy of a novel pharmacologic inducer of apoptosis in malignant peripheral
nerve sheath tumors. Cancer Res. 74, 586–597.
Chen, J., Kwon, C.H., Lin, L., Li, Y., and Parada, L.F. (2009). Inducible site-
specific recombination in neural stem/progenitor cells. Genesis 47, 122–131.
Chen, J., Li, Y., Yu, T.S., McKay, R.M., Burns, D.K., Kernie, S.G., and Parada,
L.F. (2012a). A restricted cell population propagates glioblastoma growth after
chemotherapy. Nature 488, 522–526.
Chen, Z., Pradhan, S., Liu, C., and Le, L.Q. (2012b). Skin-derived precursors as
a source of progenitors for cutaneous nerve regeneration. Stem Cells 30,
2261–2270.
Cichowski, K., and Jacks, T. (2001). NF1 tumor suppressor gene function: nar-
rowing the GAP. Cell 104, 593–604.
Cichowski, K., Shih, T.S., Schmitt, E., Santiago, S., Reilly, K., McLaughlin,
M.E., Bronson, R.T., and Jacks, T. (1999). Mouse models of tumor develop-
ment in neurofibromatosis type 1. Science 286, 2172–2176.
Coulpier, F., Le Crom, S., Maro, G.S., Manent, J., Giovannini, M., Maciorowski,
Z., Fischer, A., Gessler, M., Charnay, P., and Topilko, P. (2009). Novel features
of boundary cap cells revealed by the analysis of newly identified molecular
markers. Glia 57, 1450–1457.
Evans, D.G., Baser, M.E., McGaughran, J., Sharif, S., Howard, E., and Moran,
A. (2002). Malignant peripheral nerve sheath tumours in neurofibromatosis 1.
J. Med. Genet. 39, 311–314.
Ferner, R.E. (2007). Neurofibromatosis 1. Eur. J. Hum. Genet. 15, 131–138.
Goldstein, A.S., Huang, J., Guo, C., Garraway, I.P., and Witte, O.N. (2010).
Identification of a cell of origin for human prostate cancer. Science 329,
568–571.
Hall, A.K. (2006). Rodent sensory neuron culture and analysis. Curr. Protoc.
Neurosci. Chapter 3, Unit 3.19.
Hjerling-Leffler, J., Marmige`re, F., Heglind, M., Cederberg, A., Koltzenburg,
M., Enerba¨ck, S., and Ernfors, P. (2005). The boundary cap: a source of neuralcer Cell 26, 695–706, November 10, 2014 ª2014 Elsevier Inc. 705
Cancer Cell
Cells of Origin for Plexiform Neurofibromacrest stem cells that generatemultiple sensory neuron subtypes. Development
132, 2623–2632.
Jessen, K.R., andMirsky, R. (2005). The origin and development of glial cells in
peripheral nerves. Nat. Rev. Neurosci. 6, 671–682.
Jessen, W.J., Miller, S.J., Jousma, E., Wu, J., Rizvi, T.A., Brundage, M.E.,
Eaves, D., Widemann, B., Kim, M.O., Dombi, E., et al. (2013). MEK inhibition
exhibits efficacy in human and mouse neurofibromatosis tumors. J. Clin.
Invest. 123, 340–347.
Jett, K., and Friedman, J.M. (2010). Clinical and genetic aspects of neurofibro-
matosis 1. Genet. Med. 12, 1–11.
Joseph, N.M., Mosher, J.T., Buchstaller, J., Snider, P., McKeever, P.E., Lim,
M., Conway, S.J., Parada, L.F., Zhu, Y., and Morrison, S.J. (2008). The loss
of Nf1 transiently promotes self-renewal but not tumorigenesis by neural crest
stem cells. Cancer Cell 13, 129–140.
Kalcheim, C., and Rohrer, H. (2014). Neuroscience. Following the same nerve
track toward different cell fates. Science 345, 32–33.
Le, L.Q., and Parada, L.F. (2007). Tumor microenvironment and neurofibroma-
tosis type I: connecting the GAPs. Oncogene 26, 4609–4616.
Le, L.Q., Shipman, T., Burns, D.K., and Parada, L.F. (2009). Cell of origin and
microenvironment contribution for NF1-associated dermal neurofibromas.
Cell Stem Cell 4, 453–463.
Le, L.Q., Liu, C., Shipman, T., Chen, Z., Suter, U., and Parada, L.F. (2011).
Susceptible stages in Schwann cells for NF1-associated plexiform neurofi-
broma development. Cancer Res. 71, 4686–4695.
Leone, D.P., Genoud, S., Atanasoski, S., Grausenburger, R., Berger, P.,
Metzger, D., Macklin, W.B., Chambon, P., and Suter, U. (2003). Tamoxifen-
inducible glia-specific Cre mice for somatic mutagenesis in oligodendrocytes
and Schwann cells. Mol. Cell. Neurosci. 22, 430–440.
Li, Y., Li, Y., McKay, R.M., Riethmacher, D., and Parada, L.F. (2012).
Neurofibromin modulates adult hippocampal neurogenesis and behavioral
effects of antidepressants. J. Neurosci. 32, 3529–3539.
Limpert, A.S., Bai, S., Narayan, M., Wu, J., Yoon, S.O., Carter, B.D., and Lu,
Q.R. (2013). NF-kappaB forms a complex with the chromatin remodeler
BRG1 to regulate Schwann cell differentiation. J. Neurosci. 33, 2388–2397.
Lush, M.E., Li, Y., Kwon, C.H., Chen, J., and Parada, L.F. (2008).
Neurofibromin is required for barrel formation in the mouse somatosensory
cortex. J. Neurosci. 28, 1580–1587.
Mayes, D.A., Rizvi, T.A., Cancelas, J.A., Kolasinski, N.T., Ciraolo, G.M.,
Stemmer-Rachamimov, A.O., and Ratner, N. (2011). Perinatal or adult Nf1
inactivation using tamoxifen-inducible PlpCre each cause neurofibroma
formation. Cancer Res. 71, 4675–4685.
Parmantier, E., Lynn, B., Lawson, D., Turmaine, M., Namini, S.S., Chakrabarti,
L., McMahon, A.P., Jessen, K.R., and Mirsky, R. (1999). Schwann cell-derived
Desert hedgehog controls the development of peripheral nerve sheaths.
Neuron 23, 713–724.
Patel, A.J., Liao, C.P., Chen, Z., Liu, C., Wang, Y., and Le, L.Q. (2014). BET
bromodomain inhibition triggers apoptosis of NF1-associated malignant pe-
ripheral nerve sheath tumors through Bim induction. Cell Reports 6, 81–92.
Ratner, N., Williams, J.P., Kordich, J.J., and Kim, H.A. (2006). Schwann cell
preparation from single mouse embryos: analyses of neurofibromin function
in Schwann cells. Methods Enzymol. 407, 22–33.
Reya, T., Morrison, S.J., Clarke, M.F., and Weissman, I.L. (2001). Stem cells,
cancer, and cancer stem cells. Nature 414, 105–111.
Robinson, S.P., Langan-Fahey, S.M., Johnson, D.A., and Jordan, V.C. (1991).
Metabolites, pharmacodynamics, and pharmacokinetics of tamoxifen in rats706 Cancer Cell 26, 695–706, November 10, 2014 ª2014 Elsevier Incand mice compared to the breast cancer patient. Drug Metab. Dispos. 19,
36–43.
Rubin, J.B., and Gutmann, D.H. (2005). Neurofibromatosis type 1—amodel for
nervous system tumour formation? Nat. Rev. Cancer 5, 557–564.
Shannon, K.M., O’Connell, P., Martin, G.A., Paderanga, D., Olson, K.,
Dinndorf, P., and McCormick, F. (1994). Loss of the normal NF1 allele from
the bone marrow of children with type 1 neurofibromatosis and malignant
myeloid disorders. N. Engl. J. Med. 330, 597–601.
Staser, K., Park, S.J., Rhodes, S.D., Zeng, Y., He, Y.Z., Shew, M.A.,
Gehlhausen, J.R., Cerabona, D., Menon, K., Chen, S., et al. (2013). Normal
hematopoiesis and neurofibromin-deficient myeloproliferative disease require
Erk. J. Clin. Invest. 123, 329–334.
Tonsgard, J.H., Kwak, S.M., Short, M.P., and Dachman, A.H. (1998). CT
imaging in adults with neurofibromatosis-1: frequent asymptomatic plexiform
lesions. Neurology 50, 1755–1760.
Topilko, P., Schneider-Maunoury, S., Levi, G., Baron-Van Evercooren, A.,
Chennoufi, A.B., Seitanidou, T., Babinet, C., and Charnay, P. (1994). Krox-20
controls myelination in the peripheral nervous system. Nature 371, 796–799.
Tysnes, B.B. (2010). Tumor-initiating and -propagating cells: cells that we
would like to identify and control. Neoplasia 12, 506–515.
Vogel, K.S., Klesse, L.J., Velasco-Miguel, S., Meyers, K., Rushing, E.J., and
Parada, L.F. (1999). Mouse tumor model for neurofibromatosis type 1.
Science 286, 2176–2179.
Wang, Y., Kim, E., Wang, X., Novitch, B.G., Yoshikawa, K., Chang, L.S., and
Zhu, Y. (2012). ERK inhibition rescues defects in fate specification of Nf1-defi-
cient neural progenitors and brain abnormalities. Cell 150, 816–830.
Ward, B.A., and Gutmann, D.H. (2005). Neurofibromatosis 1: from lab bench to
clinic. Pediatr. Neurol. 32, 221–228.
Williams, J.P., Wu, J., Johansson, G., Rizvi, T.A., Miller, S.C., Geiger, H., Malik,
P., Li, W., Mukouyama, Y.S., Cancelas, J.A., and Ratner, N. (2008). Nf1 muta-
tion expands an EGFR-dependent peripheral nerve progenitor that confers
neurofibroma tumorigenic potential. Cell Stem Cell 3, 658–669.
Woodhoo, A., and Sommer, L. (2008). Development of the Schwann cell line-
age: from the neural crest to the myelinated nerve. Glia 56, 1481–1490.
Wu, J., Williams, J.P., Rizvi, T.A., Kordich, J.J., Witte, D., Meijer, D., Stemmer-
Rachamimov, A.O., Cancelas, J.A., and Ratner, N. (2008). Plexiform and
dermal neurofibromas and pigmentation are caused by Nf1 loss in desert
hedgehog-expressing cells. Cancer Cell 13, 105–116.
Xu, G.F., O’Connell, P., Viskochil, D., Cawthon, R., Robertson, M., Culver, M.,
Dunn, D., Stevens, J., Gesteland, R.,White, R., et al. (1990). The neurofibroma-
tosis type 1 gene encodes a protein related to GAP. Cell 62, 599–608.
Yang, F.C., Ingram, D.A., Chen, S., Zhu, Y., Yuan, J., Li, X., Yang, X., Knowles,
S., Horn,W., Li, Y., et al. (2008). Nf1-dependent tumors require amicroenviron-
ment containing Nf1+/– and c-kit-dependent bonemarrow. Cell 135, 437–448.
Zheng, H., Chang, L., Patel, N., Yang, J., Lowe, L., Burns, D.K., and Zhu, Y.
(2008). Induction of abnormal proliferation by nonmyelinating schwann cells
triggers neurofibroma formation. Cancer Cell 13, 117–128.
Zhu, Y., Romero, M.I., Ghosh, P., Ye, Z., Charnay, P., Rushing, E.J., Marth,
J.D., and Parada, L.F. (2001). Ablation of NF1 function in neurons induces
abnormal development of cerebral cortex and reactive gliosis in the brain.
Genes Dev. 15, 859–876.
Zhu, Y., Ghosh, P., Charnay, P., Burns, D.K., and Parada, L.F. (2002).
Neurofibromas in NF1: Schwann cell origin and role of tumor environment.
Science 296, 920–922..
